93 results on '"Marin, Mona"'
Search Results
2. Diagnostic and Immunologic Testing for Varicella in the Era of High-Impact Varicella Vaccination: An Evolving Problem.
- Author
-
Dollard S, Chen MH, Lindstrom S, Marin M, and Rota PA
- Subjects
- Humans, United States epidemiology, Chickenpox Vaccine, Herpesvirus 3, Human, Vaccination, Polymerase Chain Reaction methods, Chickenpox diagnosis, Chickenpox prevention & control
- Abstract
The clinical presentation of varicella in unvaccinated persons, with skin vesicles and scabs, has facilitated the use of rapid diagnostic methods for confirming disease. Polymerase chain reaction (PCR) assays are the diagnostic method of choice. The sharp decline in unmodified cases of varicella due to the US varicella vaccination program has led to fewer healthcare providers being familiar with varicella presentation and an increased reliance on laboratory diagnosis to confirm suspected cases. The mild, atypical presentation of the disease in vaccinated persons (fewer skin lesions, mostly maculopapular) has made it more challenging for providers to recognize and also to collect samples to detect the virus. Nonetheless, PCR is highly sensitive and specific in confirming modified disease if adequate samples are provided. While a positive PCR result is confirmatory, interpreting a negative result can prove to be more challenging in determining whether suspected varicella is falsely negative or attributable to other causes. Enhanced education of healthcare providers is critical for adequate specimen collection from modified varicella cases. In addition, more sensitive commercial serologic assays are needed in the United States for varicella immunity testing in the vaccine era., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
3. Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019.
- Author
-
Marin M, Leung J, Anderson TC, and Lopez AS
- Subjects
- Child, Adolescent, Humans, United States epidemiology, Child, Preschool, Chickenpox Vaccine, Incidence, Herpesvirus 3, Human, Immunization Programs, Vaccines, Attenuated, Antigens, Viral, Chickenpox epidemiology, Chickenpox prevention & control, Viral Vaccines
- Abstract
Surveillance is critical for monitoring vaccine impact. Varicella surveillance challenges predated varicella vaccine US licensure in 1995. Several interim steps were needed before case-based surveillance could be established in most states, and both active and passive surveillance was needed to document the vaccination program's impact on varicella incidence. By the end of the 1-dose program in 2005, incidence had declined 90% in the active surveillance areas, with significant declines occurring in all age groups within 5 years of program implementation. Additional declines occurred during the 2-dose program leading to >97% decline in incidence over the 25 years of program implementation through 2019, based on data from 4 states with continuous passive reporting. Surveillance showed that declines were highest among children and adolescents covered by the routine vaccination recommendations but occurred in all age groups. Although surveillance systems changed and were adapted to reflect evolving epidemiology, data consistently demonstrated decreasing varicella incidence following the vaccination program implementation. The vaccination program dramatically decreased virus circulation and increased community protection. Continued and improved varicella surveillance is needed to accurately monitor disease epidemiology and further guide prevention efforts., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
4. Health and Economic Impact of the United States Varicella Vaccination Program, 1996-2020.
- Author
-
Zhou F, Leung J, Marin M, Dooling KL, Anderson TC, and Ortega-Sanchez IR
- Subjects
- United States epidemiology, Humans, Immunization Programs, Vaccination, Cost of Illness, Chickenpox epidemiology, Chickenpox prevention & control, Vaccines
- Abstract
Background: The aim of this study was to evaluate the health and economic impact of the varicella vaccination program on varicella disease in the United States (US), 1996-2020., Methods: Analysis was conducted using the Centers for Disease Control and Prevention or published annual population-based varicella incidence, and varicella-associated hospitalization, outpatient visit, and mortality rates in the US population aged 0-49 years during 1996-2020 (range, 199.5-214.2 million persons) compared to before vaccination (1990-1994). Disease costs were estimated using the societal perspective. Vaccination program costs included costs of vaccine, administration, postvaccination adverse events, and travel and work time lost to obtain vaccination. All costs were adjusted to 2020 US dollars using a 3% annual discount rate. The main outcome measures were the number of varicella-associated cases, hospitalizations, hospitalization days, and premature deaths prevented; life-years saved; and net societal savings from the US varicella vaccination program., Results: Among US persons aged 0-49 years, during 1996-2020, it is estimated that more than 91 million varicella cases, 238 000 hospitalizations, 1.1 million hospitalization days, and almost 2000 deaths were prevented and 118 000 life-years were saved by the varicella vaccination program, at net societal savings of $23.4 billion., Conclusions: Varicella vaccination has resulted in substantial disease prevention and societal savings for the US over 25 years of program implementation., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
5. Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019.
- Author
-
Marin M, Lopez AS, Melgar M, Dooling K, Curns AT, and Leung J
- Subjects
- Humans, United States epidemiology, Infant, Young Adult, Adult, Herpesvirus 3, Human, Vaccination, Hospitalization, Chickenpox Vaccine, Chickenpox epidemiology, Chickenpox prevention & control, Herpes Zoster epidemiology, Herpes Zoster prevention & control
- Abstract
To describe the impact of the US varicella vaccination program on severe varicella outcomes, we analyzed varicella hospitalizations using the National Inpatient Sample 1993-2019 and varicella deaths using the National Center for Health Statistics data 1990-2019. Over 25 years of vaccination program (1995-2019), varicella hospitalizations, and deaths declined 94% and 97%, respectively, among persons aged <50 years. Most of the decline (∼90%) occurred during the 1-dose period (through 2006/2007) by attaining and maintaining high vaccination coverage; additional declines occurred during the 2-dose period, especially in the age groups covered by the 2-dose recommendation. The greatest decline for both hospitalizations and deaths (97% and >99%, respectively) was among persons aged <20 years, born during the varicella vaccination program. In the <20 age group, varicella hospitalization has become a rare event, and varicella deaths have been practically eliminated in the United States. A total of >10 500 varicella hospitalizations and 100 varicella deaths are now prevented annually in the United States as a direct result of vaccination and reduction in varicella-zoster virus circulation., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
6. Changing Epidemiology of Varicella Outbreaks in the United States During the Varicella Vaccination Program, 1995-2019.
- Author
-
Leung J, Lopez AS, and Marin M
- Subjects
- United States epidemiology, Humans, Immunization Programs, Herpesvirus 3, Human, Vaccination, Disease Outbreaks prevention & control, Chickenpox epidemiology, Chickenpox prevention & control
- Abstract
We describe the changing epidemiology of varicella outbreaks informed by past and current active and passive surveillance in the United States by reviewing data published during 1995-2015 and analyzing new data from 2016 to 2019. Varicella outbreaks were defined as ≥5 varicella cases within 1 setting and ≥1 incubation period. During the 1-dose varicella vaccination program (1995‒2006), the number of varicella outbreaks declined by 80% (2003-2006 vs 1995-1998) in 1 active surveillance area where vaccination coverage reached 90.5% in 2006. During the 2-dose program, in 7 states with consistent reporting to the Centers for Disease Control and Prevention, the number of outbreaks declined by 82% (2016-2019 vs 2005-2006). Over the entire program (1995-2019), outbreak size and duration declined from a median of 15 cases/outbreak and 45 days duration to 7 cases and 30 days duration. The proportion of outbreaks with <10 cases increased from 28% to 73%. During 2016‒2019, most (79%) outbreak cases occurred among unvaccinated or partially vaccinated persons eligible for second-dose vaccination, highlighting the potential for further varicella control., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
7. Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It's Not Gone.
- Author
-
Dooling K, Marin M, and Gershon AA
- Subjects
- United States epidemiology, Humans, Herpesvirus 3, Human, Vaccination, Memory Disorders, Public Health, Chickenpox Vaccine, Chickenpox diagnosis, Chickenpox epidemiology, Chickenpox prevention & control
- Abstract
After 25 years of varicella vaccination in the United States, classic varicella and its complications have become an uncommon occurrence. The clinical manifestation of varicella among vaccinated persons is usually modified, with fewer skin lesions, mostly maculopapular, and milder presentation. However, the potential for severe manifestations from varicella still exists among both vaccinated and unvaccinated persons, and thus healthcare providers should keep varicella in the differential diagnosis of a maculopapular or vesicular rash. The prompt recognition and diagnosis of varicella is important because when confirmed, clinical and public health measures need to be taken swiftly., Competing Interests: Potential conflicts of interest. A. A. G. receives National Institutes of Health funding (grant number R01DK093094); and has a contractual relationship with Merck through the Varicella Zoster Virus Identification Program. All other authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
8. Celebrating 25 Years of Varicella Vaccination Coverage for Children and Adolescents in the United States: A Success Story.
- Author
-
Elam-Evans LD, Valier MR, Fredua B, Zell E, Murthy BP, Sterrett N, Harris LQ, Leung J, Singleton JA, and Marin M
- Subjects
- Humans, Adolescent, United States, Vaccination Coverage, Chickenpox Vaccine, Vaccination, Herpesvirus 3, Human, Chickenpox epidemiology, Chickenpox prevention & control
- Abstract
Tracking vaccination coverage is a critical component of monitoring a vaccine program. Three different surveillance systems were used to examine trends in varicella vaccination coverage during the United States vaccination program: National Immunization Survey-Child, National Immunization Survey-Teen, and immunization information systems (IISs). The relationship of these trends to school requirements and disease decline was also examined. Among children aged 19-35 months, ≥1 dose of varicella vaccine increased from 16.0% in 1996 to 89.2% by the end of the 1-dose program in 2006, stabilizing around at least 90.0% thereafter. The uptake of the second dose was rapid after the 2007 recommendation. Two-dose coverage among children aged 7 years at 6 high-performing IIS sites increased from 2.6%-5.5% in 2006 to 86.0%-100.0% in 2020. Among adolescents aged 13-17 years, ≥2-dose coverage increased from 4.1% in 2006 to 91.9% in 2020. The proportion of adolescents with history of varicella disease declined from 69.9% in 2006 to 8.4% in 2020. In 2006, 92% of states and the District of Columbia (DC) had 1-dose daycare or school entry requirements; 88% of states and DC had 2-dose school entry requirements in the 2020-2021 school year. The successes in attaining and maintaining high vaccine coverage were paramount in the dramatic reduction of the varicella burden in the United States over the 25 years of the vaccination program, but opportunities remain to further increase coverage and decrease varicella morbidity and mortality., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
9. 25 Years of Varicella Vaccination in the United States.
- Author
-
Marin M, Seward JF, and Gershon AA
- Subjects
- United States epidemiology, Humans, Herpesvirus 3, Human, Vaccination, Chickenpox Vaccine, Chickenpox epidemiology, Chickenpox prevention & control, Herpes Zoster
- Abstract
Competing Interests: Potential conflicts of interest. A. A. G. receives National Institutes of Health funding (grant number R01DK093094); and has a contractual relationship with Merck through the Varicella Zoster Virus Identification Program. All other authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
- Published
- 2022
- Full Text
- View/download PDF
10. The Effectiveness of Varicella Vaccine: 25 Years of Postlicensure Experience in the United States.
- Author
-
Shapiro ED and Marin M
- Subjects
- United States epidemiology, Humans, Chickenpox Vaccine, Herpesvirus 3, Human, Vaccination, Vaccines, Attenuated, Antigens, Viral, Chickenpox epidemiology, Chickenpox prevention & control, Viral Vaccines
- Abstract
We summarize studies of varicella vaccine's effectiveness for prevention of varicella and lessons learned during the first 25 years of the varicella vaccination program in the United States. One dose of varicella vaccine provided moderate protection (82%-85%) against varicella of any severity and high protection (100%) against severe varicella, with some waning of protection over time. The 1-dose program (1995-2006) had a substantial impact on the incidence both of varicella and of severe outcomes (71%-90% decrease) although it did not prevent low-level community transmission and some outbreaks continued to occur in highly vaccinated populations. Two doses of varicella vaccine improved the vaccine's effectiveness by at least 10% against varicella of any severity, with further declines in the incidence both of varicella and of severe outcomes as well as in both number and size of outbreaks. There is no evidence for waning of the effectiveness of 2 doses of the vaccine., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
11. The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch.
- Author
-
Leung J, Dooling K, Marin M, Anderson TC, and Harpaz R
- Subjects
- Humans, Adult, United States epidemiology, Incidence, Birth Cohort, Herpesvirus 3, Human, Vaccination, Chickenpox epidemiology, Herpes Zoster epidemiology, Herpes Zoster prevention & control
- Abstract
When the US varicella vaccination program was introduced in 1995, its impacts on the epidemiology of herpes zoster (HZ) were not precisely known. We used a large claims database to examine HZ incidence in the US during 1998-2019 among persons aged ≥30 years (the prevaccine cohort, born before 1990), and aged 1-29 years (includes the postvaccine cohort, born since 1990). We defined incident HZ as the first instance of an outpatient or emergency department (ED) claim with an HZ diagnostic code. Additionally, we examined the proportion of HZ visits among all ED visits as a complementary method to assess for healthcare-seeking artifacts in the findings. In persons aged ≥30 years (prevaccine cohort), we observed age-specific increases in HZ incidence during the earlier study years, with decelerations in later years, starting in 2007 with oldest age groups. Similar patterns were seen when we examined HZ visits as a proportion of all ED visits. For persons aged 1-29 years, age-specific HZ incidence increased early in the study period for the oldest age groups who were born prevaccine, but later declined in a stepwise pattern once each age group was comprised of persons born in the postvaccine period. Our results, corroborated with previously published studies, do not support prior modeling predictions that the varicella vaccination program would increase HZ incidence among adult cohorts who previously experienced varicella. Our findings also suggest that continued declines in age-specific HZ incidence as varicella-vaccinated cohorts age are likely., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.)
- Published
- 2022
- Full Text
- View/download PDF
12. Communicability of varicella before rash onset: a literature review.
- Author
-
Marin M, Leung J, Lopez AS, Shepersky L, Schmid DS, and Gershon AA
- Subjects
- Asymptomatic Infections epidemiology, Chickenpox epidemiology, Exanthema epidemiology, Exanthema virology, Herpesvirus 3, Human, Humans, Chickenpox transmission
- Abstract
Varicella poses an occupational risk and a nosocomial risk for susceptible healthcare personnel and patients, respectively. Patients with varicella are thought to be infectious from 1 to 2 days before rash onset until all lesions are crusted, typically 4-7 days after onset of rash. We searched Medline, Embase, Cochrane Library and CINAHL databases to assess evidence of varicella-zoster virus (VZV) transmission before varicella rash onset. Few articles (7) contributed epidemiologic evidence; no formal studies were found. Published articles reported infectiousness at variable intervals before rash onset, between <1 day to 4 days prior to rash, with 1-2 patients for each interval. Laboratory assessment of transmission before rash was also limited (10 articles). No culture-positive results were reported. VZV DNA was identified by PCR before rash onset in only one study however, PCR does not indicate infectivity of the virus. Based on available medical literature, VZV transmission before rash onset seems unlikely, although the possibility of pre-rash, respiratory transmission cannot be entirely ruled out.
- Published
- 2021
- Full Text
- View/download PDF
13. Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine.
- Author
-
Weinmann S, Irving SA, Koppolu P, Naleway AL, Belongia EA, Hambidge SJ, Jackson ML, Klein NP, Lewin B, Liles E, Marin M, Smith N, Weintraub E, and Chun C
- Subjects
- Antibodies, Viral, Chickenpox Vaccine, Humans, Incidence, Infant, Measles-Mumps-Rubella Vaccine, Vaccines, Combined, Chickenpox epidemiology, Chickenpox prevention & control, Herpes Zoster epidemiology, Herpes Zoster prevention & control, Measles, Mumps epidemiology, Mumps prevention & control
- Abstract
Introduction: Children may receive measles-mumps-rubella (MMR) and varicella (VAR) vaccines separately or as measles-mumps-rubella-varicella (MMRV). We examined whether pediatric herpes zoster (HZ) incidence varied by pattern of varicella vaccine administration., Methods: In six integrated health systems, we examined HZ incidence among children turning 12 months old during 2003-2008. All received varicella and MMR vaccines on recommended schedules. Cases were identified through 2014 using ICD-9 codes. Incidence was examined by number of varicella vaccine doses and same-day MMR., Results: Among 199,797 children, overall HZ incidence was 18.6/100,000 person-years in the first-dose MMR + VAR group, 17.9/100,000 person-years in the MMRV group, and 7.5/100,000 person-years in the VAR-alone group. HZ incidence was lower following the second dose than before the second dose in all first-dose groups., Conclusions: HZ incidence was not meaningfully different between the MMRV and MMR + VAR first-dose groups. Overall and within first-dose groups, HZ incidence was lower among children receiving two varicella vaccine doses., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
14. Varicella in Tshuapa Province, Democratic Republic of Congo, 2009-2014.
- Author
-
Leung J, McCollum AM, Radford K, Hughes C, Lopez AS, Guagliardo SAJ, Nguete B, Likafi T, Kabamba J, Malekani J, Shongo Lushima R, Pukuta E, Karhemere S, Muyembe Tamfum JJ, Reynolds MG, Wemakoy Okitolonda E, Schmid DS, and Marin M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Democratic Republic of the Congo epidemiology, Female, Humans, Infant, Male, Middle Aged, Mpox (monkeypox) diagnosis, Mpox (monkeypox) epidemiology, Polymerase Chain Reaction, Young Adult, Chickenpox diagnosis, Chickenpox epidemiology
- Abstract
Objective: To describe varicella cases in Tshuapa Province of the Democratic Republic of the Congo identified during monkeypox surveillance., Methods: Demographic, clinical and epidemiological data were collected from each suspected monkeypox case 2009-2014. Samples were tested by PCR for both Orthopoxviruses and varicella-zoster virus (VZV); a subset of VZV-positive samples was genotyped. We defined a varicella case as a rash illness with laboratory-confirmed VZV., Results: There were 366 varicella cases were identified; 66% were ≤19 years old. Most patients had non-typical varicella rash with lesions reported as the same size and stage of evolution (86%), deep and profound (91%), on palms of hands and/or soles of feet (86%) and not itchy (49%). Many had non-typical signs and symptoms, such as lymphadenopathy (70%) and sensitivity to light (23%). A higher proportion of persons aged ≥20 years than persons aged ≤19 years had ≥50 lesions (79% vs. 65%, P = 0.007) and were bedridden (15% vs. 9%, P = 0.056). All VZV isolates genotyped from 79 varicella cases were clade 5. During the surveillance period, one possible VZV-related death occurred in a 7-year-old child., Conclusions: A large proportion of patients presented with non-typical varicella rash and clinical signs and symptoms, highlighting challenges identifying varicella in an area with endemic monkeypox. Continued surveillance and laboratory diagnosis will help in rapid identification and control of both monkeypox and varicella and improve our understanding of varicella epidemiology in Africa., (© 2019 John Wiley & Sons Ltd This article has been contributed to by US Government employees and their work is in the public domain in the USA.)
- Published
- 2019
- Full Text
- View/download PDF
15. Varicella Outbreak Surveillance in Schools in Sentinel Jurisdictions, 2012-2015.
- Author
-
Lopez AS, LaClair B, Buttery V, Zhang Y, Rosen J, Taggert E, Robinson S, Davis M, Waters C, Thomas CA, Rodriguez C, Thomas E, Tuttle J, Brantley T, Perella D, Del Rosario M, and Marin M
- Subjects
- Adolescent, Age Factors, Centers for Disease Control and Prevention, U.S., Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Child, Child, Preschool, Disease Outbreaks prevention & control, Disease Outbreaks statistics & numerical data, Herpesvirus 3, Human immunology, Humans, Immunization Programs, Infant, Schools, United States epidemiology, Vaccination, Young Adult, Chickenpox epidemiology, Sentinel Surveillance
- Abstract
Background: In 2007, a routine second dose of varicella vaccine was recommended in the United States for children aged 4 to 6 years to better control varicella-zoster virus circulation and outbreaks. Sentinel varicella outbreak surveillance was established to assess feasibility of surveillance and describe outbreaks that are occurring., Methods: Through the Centers for Disease Control and Prevention Epidemiology Laboratory Capacity funding, health departments conducted active surveillance for varicella outbreaks in schools from 2012 to 2015. Outbreaks of varicella were defined as ≥5 cases in a school within at least 1 incubation period (21 days). School nurses, healthcare providers, or laboratories reported cases and outbreaks of varicella to health departments; demographic, vaccination, and clinical data were collected., Results: Georgia, Houston, Maine, Minnesota, New York City, and Philadelphia participated in all 3 years; Puerto Rico and West Virginia participated in 2012 to 2013; and Kansas and Arkansas participated in 2014 to 2015. Twenty-nine outbreaks including 262 cases were reported. The median size of the outbreaks was 7 cases (range, 5-31 cases), and the median duration was 31 days (range, 4-100 days). Of the case-patients associated with larger outbreaks (≥8 cases), 55.4% were unvaccinated, and 15.7% and 18.1% had received 1 or 2 doses of vaccine, respectively. In small outbreaks (5-7 cases), 33.3% of case-patients were unvaccinated, and 16.7% and 38.5% had received 1 or 2 doses of vaccine, respectively., Conclusions: The majority of cases associated with outbreaks occurred in undervaccinated children (unvaccinated and 1-dose vaccine recipients). Outbreaks with a greater proportion of 2-dose vaccine recipients were smaller. Varicella outbreak surveillance is feasible, and continued monitoring of outbreaks remains important for describing the epidemiology of varicella during the 2-dose varicella vaccination program., (Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2018.)
- Published
- 2019
- Full Text
- View/download PDF
16. Varicella Vaccination Among US Adolescents: Coverage and Missed Opportunities, 2007-2014.
- Author
-
Leung J, Reagan-Steiner S, Lopez A, Jeyarajah J, and Marin M
- Subjects
- Adolescent, Chickenpox drug therapy, Chickenpox Vaccine administration & dosage, Chickenpox Vaccine adverse effects, Female, Herpesvirus 3, Human drug effects, Herpesvirus 3, Human pathogenicity, Humans, Immunization Programs methods, Immunization Programs trends, Male, Surveys and Questionnaires, United States, Vaccination statistics & numerical data, Chickenpox prevention & control, Chickenpox Vaccine therapeutic use, Immunization Programs standards, Vaccination standards
- Abstract
Context: Since 2007, 2 doses of varicella vaccine have been routinely recommended, with a catch-up second dose recommended for those who received only 1 prior dose., Objective: To examine varicella vaccination coverage with 2 or more doses and the proportions of adolescents with evidence of immunity to varicella (≥2 doses of vaccine or varicella history) during 2007-2014. To assess timing of second-dose receipt, factors associated with 2 or more vaccine doses, and missed second-dose opportunities during 2014., Design, Setting, and Participants: We used data from the 2007-2014 National Immunization Survey-Teen (NIS-Teen), which collects information on adolescents aged 13 to 17 years in the United States., Results: From 2007 to 2014, varicella vaccination coverage with 2 or more doses increased from 8.3% to 66.9% in 13- to 15-year-olds and from 3.6% to 56.7% in 16- to 17-year-olds. The proportions with evidence of immunity also increased from 68.0% to 84.1% (13- to 15-year-olds) and 78.6% to 83.4% (16- to 17-year-olds). In 2014, 13.4% of 13- to 15-year-olds and 3.2% of 16- to 17-year-olds had received their second dose at 4 to 6 years of age. Factors most significantly associated with lower coverage with 2 or more doses were not having an 11- to 12-year well-child visit, not receiving an adolescent vaccine, and residence in a state with no 2-dose immunization school entry requirement. Seventy-seven percent of 1-dose vaccinated adolescents had 1 or more missed opportunities to receive their second dose; if were they not missed, 2-dose coverage would have increased from 79.5% to 94.8%., Conclusions: Levels of varicella vaccination coverage with 2 or more doses and the proportion of adolescents with evidence of immunity increased from 2007 to 2014, though 16% lacked evidence of immunity in 2014. Although catch-up campaigns have succeeded, missed vaccination opportunities persist.
- Published
- 2019
- Full Text
- View/download PDF
17. Maritime varicella illness and death reporting, U.S., 2010-2015.
- Author
-
Rice ME, Bannerman M, Marin M, Lopez AS, Lewis MM, Stamatakis CE, and Regan JJ
- Subjects
- Adolescent, Adult, Chickenpox prevention & control, Child, Child, Preschool, Disease Notification, Female, Humans, Infant, Male, Middle Aged, Public Health, Quarantine, United States epidemiology, Young Adult, Chickenpox epidemiology, Chickenpox mortality, Ships, Travel
- Abstract
Background: Ships destined for, or departing from, U.S. ports of entry must report certain signs and symptoms of potentially communicable diseases of public health interest among travelers to the Division of Global Migration and Quarantine (DGMQ) at the Centers for Disease Control and Prevention., Methods: We reviewed ships' varicella case and outbreak reports from January 2010 through December 2015., Results: DGMQ received 967 reports of varicella and 13 reports of herpes zoster. Most varicella case-patients were 20-49 years of age (84.7%, 472/557) and were cruise ship crew members (78.4%, 758/967). Most often, cruise ship crew member case-patients were born in or held passports from Indonesia (21.7%, 80/369), Philippines (17.6%, 65/369), or India (17.3%, 64/369). Ninety-nine varicella outbreaks were reported, including 439 varicella cases and one herpes zoster case; 97 (98.0%) outbreaks occurred on cruise ships, and 90.2% of associated cases were among crew members (397/440). Most varicella cases were in crew members, who are adults often from tropical regions where varicella immunity is acquired later in childhood or young adulthood or without varicella vaccination programs., Conclusion: Varicella vaccination as appropriate for susceptible travelers, particularly crew members, before maritime travel may decrease risk of varicella infection and prevent outbreaks on ships., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
18. Update on trends in varicella mortality during the varicella vaccine era-United States, 1990-2016.
- Author
-
Leung J and Marin M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Middle Aged, Survival Analysis, United States epidemiology, Young Adult, Chickenpox mortality, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Chickenpox Vaccine immunology
- Abstract
We reported previously that the annual average mortality rate in the United States in 2008-2011 for varicella listed as the underlying cause declined 87% compared with the prevaccine period (1990-1994). Here, we update the analysis with five additional years of data. We used varicella death data from the 2012-2016 Mortality Multiple Cause-of Death records to calculate mortality rates during 2012-2016 and trends since the prevaccine period and end of 1-dose vaccination program (2005-2007). The annual average age-adjusted mortality rate for varicella as the underlying cause was 0.03 per million population during 2012-2016, a 94% reduction from prevaccine years and a 47% reduction from 2005-2007. Varicella deaths continue to decline due to the varicella vaccination program in the United States.
- Published
- 2018
- Full Text
- View/download PDF
19. Varicella outbreak in a highly-vaccinated school population in Beijing, China during the voluntary two-dose era.
- Author
-
Suo L, Lu L, Wang Q, Yang F, Wang X, Pang X, Marin M, and Wang C
- Subjects
- Beijing epidemiology, Chickenpox virology, Child, Child, Preschool, Cohort Studies, Female, Herpesvirus 3, Human isolation & purification, Humans, Immunization Schedule, Incidence, Male, Parents, Risk Factors, Schools, Students, Surveys and Questionnaires, Vaccination, Chickenpox epidemiology, Chickenpox Vaccine administration & dosage, Disease Outbreaks prevention & control, Vaccination Coverage
- Abstract
Background: Two-dose varicella vaccination has been available in Beijing since 2012 in the private sector. We investigated a varicella outbreak in a highly vaccinated elementary school population., Methods: A cohort study was carried out and a varicella case was defined as an acute onset of generalized maculopapulovesicular rash without other apparent cause in a student attending the school from March 29 through May 17, 2015. Breakthrough varicella was defined as varicella >42days after the last vaccine dose among both 1- or 2-dose varicella vaccine recipients. Vaccination information was collected from immunization records; information on prior varicella and clinical presentations was collected by surveying students' parents., Results: Of the 1056 students in the school, 1027 (97.3%) reported no history of varicella. Prior to the outbreak, 98.6% of students had received ≥1 dose of varicella vaccine, and most (63.2%) students received two doses. Twenty varicella cases were identified for an overall attack rate of 2.0%. Half of the cases occurred in the classroom of the index case-patient, a two-dose recipient who was not isolated after symptom onset. Breakthrough varicella accounted for 95% of cases (19/20) with attack rates of 14.3% (1/7), 1.6% (6/362) and 2.0% (13/649) among unvaccinated, one-dose, and two-dose students, respectively. Most case-patients (18/20, 90%) had <50 lesions. No difference in clinical presentations was found between one-dose and two-dose recipients with breakthrough varicella., Conclusion: Moderate two-dose varicella vaccine coverage was insufficient to prevent a varicella outbreak. Two-dose recipients with breakthrough varicella are contagious. High two-dose varicella vaccine coverage and timely isolation of cases may be needed for varicella outbreak prevention in the two-dose era., (Published by Elsevier Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
20. Notes from the Field: Varicella Fatality on a Cargo Vessel - Puerto Rico, 2015.
- Author
-
Ellis M, Luna-Pinto C, George T, Regan JJ, Marin M, Lopez A, Rivera-Garcia B, and Tardivel K
- Subjects
- Centers for Disease Control and Prevention, U.S., Chickenpox prevention & control, Fatal Outcome, Humans, Male, Middle Aged, Pneumonia, Viral prevention & control, Puerto Rico, United States, Chickenpox diagnosis, Herpesvirus 3, Human isolation & purification, Pneumonia, Viral diagnosis, Ships
- Published
- 2017
- Full Text
- View/download PDF
21. Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature review.
- Author
-
Leung J, Broder KR, and Marin M
- Subjects
- Humans, Chickenpox immunology, Chickenpox prevention & control, Chickenpox Vaccine immunology, Herpesvirus 3, Human immunology
- Abstract
Introduction: Varicella vaccines are highly effective at preventing disease, but varicella may occur among vaccinated persons (termed breakthrough varicella). Breakthrough varicella is generally mild, but severe cases have been reported. The objective of this review is to describe severe breakthrough varicella. Areas covered: We conducted a systematic review of articles published during 1974-2016. A total of 34 articles were included in our review: 21 described breakthrough varicella with disseminated varicella-zoster virus (VZV) infection with other organ involvement in addition to skin (none among two-dose vaccinees); 9 described hospitalized breakthrough varicella without mention of other organ involvement in addition to skin (of which 2 reported 4 two-dose vaccinees); and 4 described both. A total of 52-60 unique breakthrough varicella cases with disseminated VZV infection with other organ involvement in addition to skin reported with the following complications, not mutually exclusive: pneumonia (n = 8-9 cases), neurologic (n = 18-24 cases), hematologic (n = 10-11 cases), ocular (n = 5 cases), renal (n = 2 cases), hepatic (n = 3 cases), secondary infection with bacteremia or sepsis (n = 8 cases), and other complication (n = 4 cases). There were 6 cases of fatal breakthrough varicella. Expert commentary: With >31 million doses distributed annually worldwide since 2007, severe breakthrough varicella can occur but they appear to be uncommon.
- Published
- 2017
- Full Text
- View/download PDF
22. Update on Incidence of Herpes Zoster Among Children and Adolescents After Implementation of Varicella Vaccination, Antelope Valley, CA, 2000 to 2010.
- Author
-
Civen R, Marin M, Zhang J, Abraham A, Harpaz R, Mascola L, and Bialek SR
- Subjects
- Adolescent, Adult, California epidemiology, Child, Female, Humans, Incidence, Male, Population Surveillance, Young Adult, Chickenpox epidemiology, Chickenpox prevention & control, Chickenpox Vaccine, Vaccination statistics & numerical data
- Abstract
Background: Changes in herpes zoster (HZ) epidemiology are expected with childhood varicella vaccination. We reported previously that during 2000 to 2006 HZ incidence decreased 55% in children <10 years of age, while among 10- to 19-year olds it increased by 63%. We update the analysis with 4 additional years of data., Methods: Population-based active surveillance was conducted for HZ in Antelope Valley, California. Structured telephone interviews and medical chart reviews collected data on demographics, varicella vaccinations, disease histories and clinical information. We calculated HZ incidence for 2007 to 2010 and assessed trends since 2000., Results: Among children <10 years of age, HZ incidence continued the decreasing trend previously reported. During 2007 to 2010, the average incidence was 12.8 cases/100,000 children compared with 41.6 cases/100,000 children during 2000 to 2006, a 69% decline (P < 0.0001). For the 10- to 19-year olds, during 2007 to 2010 HZ incidence did not continue the increasing trend reported from 2000 to 2006; lower rates than in 2006 were observed in 3 of the 4 additional years evaluated. During 2007 to 2010 the average incidence was 78.2 cases/100,000 children compared with 68.0 cases/100,000 children during 2000 to 2006, a 13% increase (P = 0.123), with substantial fluctuation in annual rates throughout the 11 years of surveillance., Conclusions: During the mature varicella vaccination program, declines in HZ incidence among children <10 years of age continued through 2010. Among the 10- to 19-year olds, the increase reported through 2006 did not continue further and lower rates than in 2006 were observed through 2010. Widespread use of varicella vaccine could reduce HZ incidence among vaccinated populations. Ongoing monitoring of HZ incidence is needed to detect and understand changes in HZ epidemiology in the varicella vaccine era.
- Published
- 2016
- Full Text
- View/download PDF
23. Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program - United States, 2005-2014.
- Author
-
Lopez AS, Zhang J, and Marin M
- Subjects
- Adolescent, Child, Child, Preschool, Humans, Immunization Programs, Immunization Schedule, Incidence, Infant, Program Evaluation, United States epidemiology, Young Adult, Chickenpox epidemiology, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Disease Outbreaks prevention & control, Population Surveillance
- Abstract
Before availability of varicella vaccine in the United States, an estimated 4 million varicella cases, 11,000-13,500 varicella-related hospitalizations, and 100-150 varicella-related deaths occurred annually. The varicella vaccination program was implemented in the United States in 1996 as a 1-dose routine childhood program. Based on data from two varicella active surveillance sites, the varicella vaccination program led to 90% decline in incidence over the next decade (1). However, because of continued varicella outbreaks, a routine 2-dose schedule (at ages 12-15 months and 4-6 years) was recommended and has been in place since 2006 (2). The declines in incidence (1,3-6) made it feasible for states to implement varicella case-based surveillance and to report varicella data to CDC through the National Notifiable Diseases Surveillance System (NNDSS). State data have become the primary source for monitoring trends in varicella incidence nationally (7). Using NNDSS data, CDC previously reported nationwide declines in varicella incidence of 72% from the end of the 1-dose to the early years of the 2-dose varicella vaccination program (2006-2010) (7). This report updates varicella incidence trends to include the most recent years in the 2-dose varicella vaccination program. Between the period 2005-2006 (before the 2-dose recommendation) and 2013-2014, overall varicella incidence declined 84.6%, with the largest declines reported in children aged 5-9 years (89.3%) and 10-14 years (84.8%). The availability of varicella-specific data varied over time. During the last 2 years examined (2013 and 2014), completeness of reporting of two critical variables monitored by CDC, vaccination status (receipt of at least 1 dose of varicella vaccine) of cases and severity of disease based on number of lesions, were 54.2% and 39.1%, respectively. State and local health departments, in collaboration with CDC, should continue working to improve reporting of cases and completeness of critical varicella-specific variables to better monitor impact of the varicella vaccination program.
- Published
- 2016
- Full Text
- View/download PDF
24. Varicella immunization requirements for US colleges: 2014-2015 academic year.
- Author
-
Leung J, Marin M, Leino V, Even S, and Bialek SR
- Subjects
- Chickenpox Vaccine therapeutic use, Humans, Mandatory Programs, Students, United States, Universities, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Disease Outbreaks prevention & control, Health Policy, Vaccination statistics & numerical data
- Abstract
Objective: To obtain information on varicella prematriculation requirements in US colleges for undergraduate students during the 2014-2015 academic year., Participants: Health care professionals and member schools of the American College Health Association (ACHA)., Methods: An electronic survey was sent to ACHA members regarding school characteristics and whether schools had policies in place requiring that students show proof of 2 doses of varicella vaccination for school attendance., Results: Only 27% (101/370) of schools had a varicella prematriculation requirement for undergraduate students. Only 68% of schools always enforced this requirement. Private schools, 4-year schools, northeastern schools, those with <5,000 students, and schools located in a state with a 2-dose varicella vaccine mandate were significantly more likely to have a varicella prematriculation requirement., Conclusions: A small proportion of US colleges have a varicella prematriculation requirement for varicella immunity. College vaccination requirements are an important tool for controlling varicella in these settings.
- Published
- 2016
- Full Text
- View/download PDF
25. Global Varicella Vaccine Effectiveness: A Meta-analysis.
- Author
-
Marin M, Marti M, Kambhampati A, Jeram SM, and Seward JF
- Subjects
- Chickenpox epidemiology, Child, Global Health, Humans, Treatment Outcome, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Disease Outbreaks prevention & control, Vaccination methods
- Abstract
Context: Several varicella vaccines are available worldwide. Countries with a varicella vaccination program use 1- or 2-dose schedules., Objective: We examined postlicensure estimates of varicella vaccine effectiveness (VE) among healthy children., Data Sources: Systematic review and descriptive and meta-analysis of Medline, Embase, Cochrane libraries, and CINAHL databases for reports published during 1995-2014., Study Selection: Publications that reported original data on dose-specific varicella VE among immunocompetent children., Data Extraction: We used random effects meta-analysis models to obtain pooled one dose VE estimates by disease severity (all varicella and moderate/severe varicella). Within each severity category, we assessed pooled VE by vaccine and by study design. We used descriptive statistics to summarize 1-dose VE against severe disease. For 2-dose VE, we calculated pooled estimates against all varicella and by study design., Results: The pooled 1-dose VE was 81% (95% confidence interval [CI]: 78%-84%) against all varicella and 98% (95% CI: 97%-99%) against moderate/severe varicella with no significant association between VE and vaccine type or study design (P > .1). For 1 dose, median VE for prevention of severe disease was 100% (mean = 99.4%). The pooled 2-dose VE against all varicella was 92% (95% CI: 88%-95%), with similar estimates by study design., Limitations: VE was assessed primarily during outbreak investigations and using clinically diagnosed varicella., Conclusions: One dose of varicella vaccine was moderately effective in preventing all varicella and highly effective in preventing moderate/severe varicella, with no differences by vaccine. The second dose adds improved protection against all varicella., (Copyright © 2016 by the American Academy of Pediatrics.)
- Published
- 2016
- Full Text
- View/download PDF
26. Trends in varicella mortality in the United States: Data from vital statistics and the national surveillance system.
- Author
-
Leung J, Bialek SR, and Marin M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Epidemiological Monitoring, Female, Humans, Immunization Programs, Infant, Male, Middle Aged, Survival Analysis, United States epidemiology, Vital Statistics, Young Adult, Chickenpox mortality
- Abstract
This manuscript describes trends in US varicella mortality using national vital statistics system data for 2008-2011, the first years of the routine 2-dose varicella vaccination program, and characteristics of varicella deaths reported to CDC during 1996-2013. We obtained data on deaths with varicella as underlying or contributing cause from the 2008-2011 Mortality Multiple Cause-of Death records and calculated rates to compare with the prevaccine and mature 1-dose varicella vaccination program eras. We also reviewed available records of varicella deaths reported to CDC through the national varicella death surveillance. The annual average age-adjusted mortality rate for varicella as the underlying cause was 0.05 per million population during 2008-2011, an 87% reduction from the prevaccine years. Varicella deaths among persons aged <20 y declined by 99% in 2008-2011 compared with prevaccine years. There was a 70% decline in varicella mortality rates among those <20 y in 2008-2011 compared to 2005-2007. Among the 83 deaths reported to CDC during 1996-2013 classified as likely due to varicella, 24 (29%) were among immunocompromised individuals. Five were among persons previously vaccinated with 1 dose of varicella vaccine. In conclusion, although the US varicella vaccination program has significantly reduced varicella disease burden, there are still opportunities to prevent varicella and its associated morbidity and mortality through routine varicella vaccination, catch-up vaccination, and ensuring that household contacts of immunocompromised persons have evidence of immunity.
- Published
- 2015
- Full Text
- View/download PDF
27. Challenges with controlling varicella in prison settings: experience of California, 2010 to 2011.
- Author
-
Leung J, Lopez AS, Tootell E, Baumrind N, Mohle-Boetani J, Leistikow B, Harriman KH, Preas CP, Cosentino G, Bialek SR, and Marin M
- Subjects
- California epidemiology, Chickenpox economics, Chickenpox transmission, Chickenpox Vaccine administration & dosage, Costs and Cost Analysis, Disease Outbreaks economics, Humans, Infection Control economics, Mass Screening, Prisons economics, Chickenpox epidemiology, Disease Outbreaks prevention & control, Infection Control methods, Prisons organization & administration, Prisons statistics & numerical data
- Abstract
This article describes the epidemiology of varicella in one state prison in California during 2010 and 2011, control measures implemented, and associated costs. Eleven varicella cases were reported, of which nine were associated with two outbreaks. One outbreak consisted of three cases and the second consisted of six cases with two generations of spread. Among exposed inmates serologically tested, 98% (643/656) were varicella-zoster virus seropositive. The outbreaks resulted in > 1,000 inmates exposed, 444 staff exposures, and > $160,000 in costs. The authors documented the challenges and costs associated with controlling and managing varicella in a prison setting. A screening policy for evidence of varicella immunity for incoming inmates and staff and vaccination of susceptible persons has the potential to mitigate the impact of future outbreaks and reduce resources necessary to manage cases and outbreaks., (© The Author(s) 2014.)
- Published
- 2014
- Full Text
- View/download PDF
28. Fatal varicella due to the vaccine-strain varicella-zoster virus.
- Author
-
Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS, Bialek SR, and Marin M
- Subjects
- Acyclovir therapeutic use, Antiviral Agents therapeutic use, Chickenpox complications, Chickenpox drug therapy, Fatal Outcome, Female, Humans, Infant, Multiple Organ Failure etiology, Multiple Organ Failure pathology, Sepsis drug therapy, Sepsis etiology, Sepsis pathology, Treatment Failure, United States, Chickenpox chemically induced, Chickenpox Vaccine administration & dosage, Chickenpox Vaccine adverse effects, Herpesvirus 3, Human isolation & purification
- Abstract
We describe a death in a 15-mo-old girl who developed a varicella-like rash 20 d after varicella vaccination that lasted for 2 mo despite acyclovir treatment. The rash was confirmed to be due to vaccine-strain varicella-zoster virus (VZV). This is the first case of fatal varicella due to vaccine-strain VZV reported from the United States. The patient developed severe respiratory complications that worsened with each new crop of varicella lesions; vaccine-strain VZV was detected in the bronchial lavage specimen. Sepsis and multi-organ failure led to death. The patient did not have a previously diagnosed primary immune deficiency, but her failure to thrive and repeated hospitalizations early in life (starting at 5 mo) for presumed infections and respiratory compromise treated with corticosteroids were suggestive of a primary or acquired immune deficiency. Providers should monitor for adverse reactions after varicella vaccination. If severe adverse events develop, acyclovir should be administered as soon as possible. The possibility of acyclovir resistance and use of foscarnet should be considered if lesions do not improve after 10 d of treatment (or if they become atypical [e.g., verrucous]). Experience with use of varicella vaccine indicates that the vaccine has an excellent safety profile and that serious adverse events are very rare and mostly described in immunocompromised patients. The benefit of vaccination in preventing severe disease and mortality outweigh the low risk of severe events occurring after vaccination.
- Published
- 2014
- Full Text
- View/download PDF
29. Near elimination of varicella deaths in the US after implementation of the vaccination program.
- Author
-
Marin M, Zhang JX, and Seward JF
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, United States epidemiology, Young Adult, Chickenpox mortality, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Vaccination trends
- Abstract
Objective: Varicella has been preventable by vaccination in the United States since 1995. Previous studies reported a 66% decline in mortality rate during the first 6 years of the program. Since then, vaccination coverage has increased substantially. We updated the analysis of US varicella mortality for 2002-2007 and assessed the impact of the first 12 years of the US varicella vaccination program on varicella deaths., Methods: National data on deaths for which varicella was listed as an underlying or contributing cause were obtained from the Mortality Multiple Cause-of-Death records from the US National Center for Health Statistics. We calculated the age-adjusted and age-specific mortality rates for 2002-2007 and trends since the prevaccine years., Results: During the 12 years of the mostly 1-dose US varicella vaccination program, the annual average mortality rate for varicella listed as the underlying cause declined 88%, from 0.41 per million population in 1990-1994 to 0.05 per million population in 2005-2007. The decline occurred in all age groups, and there was an extremely high reduction among children and adolescents younger than 20 years (97%) and among subjects younger than 50 years overall (96%). In the last 6 years analyzed (2002-2007), a total of 3 deaths per age range were reported among children aged 1 to 4 and 5 to 9 years, compared with an annual average of 13 and 16 deaths, respectively, during the prevaccine years., Conclusions: The impressive decline in varicella deaths can be directly attributed to successful implementation of the 1-dose vaccination program. With the current 2-dose program, there is potential that these most severe outcomes of a vaccine-preventable disease could be eliminated.
- Published
- 2011
- Full Text
- View/download PDF
30. Incremental effectiveness of second dose varicella vaccination for outbreak control at an elementary school in Philadelphia, pennsylvania, 2006.
- Author
-
Nguyen MD, Perella D, Watson B, Marin M, Renwick M, and Spain CV
- Subjects
- Chickenpox Vaccine immunology, Child, Child, Preschool, Female, Humans, Incidence, Male, Philadelphia epidemiology, Schools, Surveys and Questionnaires, Treatment Outcome, Chickenpox epidemiology, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Disease Outbreaks, Immunization, Secondary methods
- Abstract
Background: In 2006, the Philadelphia Department of Public Health conducted an investigation of a varicella outbreak at an elementary school in which second-dose vaccination for outbreak control (VOC) was implemented. We evaluated the effectiveness of this intervention., Methods: Self-administered questionnaires collected varicella disease and vaccination information. Students eligible for second-dose VOC were 1-dose vaccine recipients without prior varicella disease. A breakthrough varicella case was defined as a maculopapulovesicular rash in a student with onset >42 days after 1-dose vaccination without other apparent cause. Vaccine effectiveness was evaluated using survival analysis techniques and analyzed by vaccine status (first dose versus second dose). Multivariable Cox proportional hazard models were used to identify statistical interactions and adjust for confounders., Results: The questionnaire response rate was 92% (342/370). Of the 286 eligible students, 187 (65%) received a second-dose VOC. The crude attack rate was 9/187 (5%) among second-dose VOC recipients; 43/99 (43%) among 1-dose recipients, and 5/6 (83%) among unvaccinated students. Second-dose VOC recipients had milder rashes, compared with 1-dose or unvaccinated students. The adjusted incremental second-dose vaccine effectiveness was 76% (95% confidence interval: 44%-90%) for students with classroom exposure. Incremental effectiveness was similar (79%) when we extended the immune response time from 4 days to 7 days after second-dose VOC., Conclusions: Second-dose VOC resulted in a substantial reduction in varicella incidence for students with classroom exposure. Until high rates of routine second-dose vaccine coverage are achieved, clinicians should consider second-dose VOC an appropriate intervention to reduce disease transmission in institution-based outbreaks.
- Published
- 2010
- Full Text
- View/download PDF
31. Varicella prevention in the United States: a review of successes and challenges.
- Author
-
Marin M, Meissner HC, and Seward JF
- Subjects
- Chickenpox epidemiology, Child, Herpesvirus 3, Human immunology, Humans, Prevalence, United States epidemiology, Viral Vaccines therapeutic use, Chickenpox prevention & control, Infection Control trends, Vaccination trends
- Abstract
Objective: In 1995, the United States was the first country to introduce a universal 1-dose childhood varicella vaccination program. In 2006, the US varicella vaccine policy was changed to a routine 2-dose childhood program, with catchup vaccination for older children. The objective of this review was to summarize the US experience with the 1-dose varicella vaccination program, present the evidence considered for the policy change, and outline future challenges of the program., Methods: We conducted a review of publications identified by searching PubMed for the terms "varicella," "varicella vaccine," and "herpes zoster." The search was limited to US publications except for herpes zoster; we reviewed all published literature on herpes zoster incidence., Results: A single dose of varicella vaccine was 80% to 85% effective in preventing disease of any severity and >95% effective in preventing severe varicella and had an excellent safety profile. The vaccination program reduced disease incidence by 57% to 90%, hospitalizations by 75% to 88%, deaths by >74%, and direct inpatient and outpatient medical expenditures by 74%. The decline of cases plateaued between 2003 and 2006, and outbreaks continued to occur, even among highly vaccinated school populations. Compared with children who received 1 dose, in 1 clinical trial, 2-dose vaccine recipients developed in a larger proportion antibody titers that were more likely to protect against breakthrough disease and had a 3.3-fold lower risk for breakthrough disease and higher vaccine efficacy. Two studies showed no increase in overall herpes zoster incidence, whereas 2 others showed an increase., Conclusions: A decade of varicella prevention in the United States has resulted in a dramatic decline in disease; however, even with high vaccination coverage, the effectiveness of 1 dose of vaccine did not generate sufficient population immunity to prevent community transmission. A 2-dose varicella vaccine schedule, therefore, was recommended for children in 2006. Data are inconclusive regarding an effect of the varicella vaccination program on herpes zoster epidemiology.
- Published
- 2008
- Full Text
- View/download PDF
32. Varicella among adults: data from an active surveillance project, 1995-2005.
- Author
-
Marin M, Watson TL, Chaves SS, Civen R, Watson BM, Zhang JX, Perella D, Mascola L, and Seward JF
- Subjects
- Adolescent, Adult, Age Distribution, California epidemiology, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Child, Child, Preschool, Humans, Immunization Programs, Incidence, Infant, Infant, Newborn, Pennsylvania epidemiology, Vaccination, Chickenpox epidemiology, Population Surveillance methods
- Abstract
We report detailed population-based data on varicella among adults. In 2 US varicella active surveillance sites with high vaccine coverage among young children, the incidence of varicella among adults declined 74% during 1995-2005. A low proportion (3%) of adults with varicella had been vaccinated, with no improvement over the decade of program implementation, suggesting that the decline was likely secondary to herd-immunity effects. Compared with children, adults had more severe varicella in terms of both clinical presentation and frequency of complications. However, <30% of adults with varicella were treated with acyclovir. Among adolescents, illness severity was intermediate between that in children and adults. Varicella cases are preventable through vaccination. As we enter the second decade of the varicella vaccination program in the United States, we need to ensure that susceptible adolescents and adults are adequately protected from varicella by vaccination and that those who acquire varicella are appropriately treated with effective antiviral treatment.
- Published
- 2008
- Full Text
- View/download PDF
33. Varicella vaccine effectiveness in the US vaccination program: a review.
- Author
-
Seward JF, Marin M, and Vázquez M
- Subjects
- Adolescent, Case-Control Studies, Child, Child, Preschool, Cohort Studies, Disease Outbreaks prevention & control, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, United States epidemiology, Vaccination, Chickenpox epidemiology, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Chickenpox Vaccine therapeutic use, Immunization Programs
- Abstract
Varicella vaccine (Varivax, Merck) has been available in the United States since 1995. We reviewed published results of postlicensure studies of vaccine effectiveness. Among 19 studies, 17 reported on the effectiveness of vaccine received before exposure, and 2 reported on effectiveness after exposure. Studies used retrospective and prospective cohort, case-control, and secondary attack rate (household contact) designs. The majority of estimates assessed protection against clinically diagnosed varicella. One dose of varicella vaccine was 84.5% effective (median; range, 44%-100%) in preventing all varicella and 100% effective (mean and median) in preventing severe varicella. When administered after exposure, varicella vaccine was highly effective in preventing or modifying varicella. Although 1 dose of varicella vaccine has provided excellent protection, a higher degree of effectiveness is needed in order to interrupt transmission and to prevent outbreaks in settings with high contact rates. Monitoring the effectiveness of the newly recommended 2-dose childhood vaccine schedule for varicella vaccine is a priority.
- Published
- 2008
- Full Text
- View/download PDF
34. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).
- Author
-
Marin M, Güris D, Chaves SS, Schmid S, and Seward JF
- Subjects
- Acyclovir therapeutic use, Adolescent, Adult, Antibodies, Viral biosynthesis, Antiviral Agents therapeutic use, Chickenpox economics, Chickenpox epidemiology, Child, Child, Preschool, Drug Storage, Herpes Zoster epidemiology, Humans, Immunization Schedule, Infant, Vaccines, Combined administration & dosage, Vaccines, Combined adverse effects, Vaccines, Combined economics, Vaccines, Combined immunology, Vaccines, Combined supply & distribution, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Chickenpox Vaccine adverse effects, Chickenpox Vaccine economics, Chickenpox Vaccine immunology, Chickenpox Vaccine supply & distribution, Measles-Mumps-Rubella Vaccine administration & dosage, Measles-Mumps-Rubella Vaccine adverse effects, Measles-Mumps-Rubella Vaccine economics, Measles-Mumps-Rubella Vaccine immunology, Measles-Mumps-Rubella Vaccine supply & distribution
- Abstract
Two live, attenuated varicella zoster virus-containing vaccines are available in the United States for prevention of varicella: 1) a single-antigen varicella vaccine (VARIVAX, Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 1995 for use among healthy children aged > or = 12 months, adolescents, and adults; and 2) a combination measles, mumps, rubella, and varicella vaccine (ProQuad, Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 2005 for use among healthy children aged 12 months-12 years. Initial Advisory Committee on Immunization Practices (ACIP) recommendations for prevention of varicella issued in 1995 (CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1996;45 [No. RR-11]) included routine vaccination of children aged 12-18 months, catch-up vaccination of susceptible children aged 19 months-12 years, and vaccination of susceptible persons who have close contact with persons at high risk for serious complications (e.g., health-care personnel and family contacts of immunocompromised persons). One dose of vaccine was recommended for children aged 12 months-12 years and 2 doses, 4-8 weeks apart, for persons aged > or = 13 years. In 1999, ACIP updated the recommendations (CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1999;48 [No. RR-6]) to include establishing child care and school entry requirements, use of the vaccine following exposure and for outbreak control, use of the vaccine for certain children infected with human immunodeficiency virus, and vaccination of adolescents and adults at high risk for exposure or transmission. In June 2005 and June 2006, ACIP adopted new recommendations regarding the use of live, attenuated varicella vaccines for prevention of varicella. This report revises, updates, and replaces the 1996 and 1999 ACIP statements for prevention of varicella. The new recommendations include 1) implementation of a routine 2-dose varicella vaccination program for children, with the first dose administered at age 12-15 months and the second dose at age 4-6 years; 2) a second dose catch-up varicella vaccination for children, adolescents, and adults who previously had received 1 dose; 3) routine vaccination of all healthy persons aged > or = 13 years without evidence of immunity; 4) prenatal assessment and postpartum vaccination; 5) expanding the use of the varicella vaccine for HIV-infected children with age-specific CD4+ T lymphocyte percentages of 15%-24% and adolescents and adults with CD4+ T lymphocyte counts > or = 200 cells/microL; and 6) establishing middle school, high school, and college entry vaccination requirements. ACIP also approved criteria for evidence of immunity to varicella.
- Published
- 2007
35. Physician attitudes regarding breakthrough varicella disease and a potential second dose of varicella vaccine.
- Author
-
Davis MM, Marin M, Cowan AE, Guris D, and Clark SJ
- Subjects
- Child, Child, Preschool, Humans, Surveys and Questionnaires, Attitude of Health Personnel, Chickenpox prevention & control, Chickenpox Vaccine administration & dosage, Physicians
- Abstract
Objective: We assessed physicians' attitudes about the 1-dose varicella vaccination program and whether physicians think a 2-dose recommendation is needed to reduce the risk of breakthrough disease., Methods: We conducted a national mail survey of a random sample of 550 pediatricians and 550 family physicians from April to June 2005. Physicians who provide outpatient primary care to children < or = 6 years of age were eligible for analysis., Results: Surveys were returned by 727 respondents, for a response rate of 69%; 610 physicians were eligible. Most respondents (94%) recommend routine 1-dose varicella vaccination, and 79% have seen breakthrough disease in the past 5 years (95% of pediatricians and 58% of family physicians). The majority (68%) agreed or strongly agreed that the current burden of breakthrough disease is acceptable. Only 38% (46% of pediatricians and 28% of family physicians) agreed or strongly agreed that a second dose of varicella vaccine is needed to address the burden of breakthrough disease, whereas 40% were neutral. However, if the Advisory Committee on Immunization Practices were to recommend a second dose of varicella vaccine, then 65% of pediatricians and 39% of family physicians would likely follow the recommendation. Most respondents (78%) would be more willing to recommend a second dose if a combination measles-mumps-rubella-varicella vaccine was available., Conclusions: Pediatricians and family physicians support the 1-dose varicella vaccination program. A new Advisory Committee on Immunization Practices recommendation for a second dose of varicella vaccine for children was issued after the survey (in June 2006). Two of 3 pediatricians and 2 of 5 family physicians stated that they would adopt a 2-dose recommendation in practice; rates of adoption may be bolstered with current availability of measles-mumps-rubella-varicella vaccine and harmonization of the varicella vaccination schedule with that of measles-mumps-rubella vaccine.
- Published
- 2007
- Full Text
- View/download PDF
36. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003.
- Author
-
Marin M, Nguyen HQ, Keen J, Jumaan AO, Mellen PM, Hayes EB, Gensheimer KF, Gunderman-King J, and Seward JF
- Subjects
- Chickenpox prevention & control, Child, Child, Preschool, Female, Humans, Maine epidemiology, Male, Risk Factors, Severity of Illness Index, Surveys and Questionnaires, Treatment Failure, Chickenpox epidemiology, Chickenpox Vaccine, Disease Outbreaks, Vaccination statistics & numerical data
- Abstract
Objective: During December 2002 to January 2003, a varicella outbreak occurred in an elementary school in Maine. Just 1 month before detecting the outbreak, Maine implemented varicella vaccine requirements for child care but did not require vaccination for school entry. We investigated this outbreak to examine reasons for its occurrence, including vaccine failure., Methods: A self-administered questionnaire was sent to all students' parents to determine student disease status, medical conditions, and vaccination status, which was further confirmed by review of medical records. Parental reporting of chickenpox/varicella that occurred since September 1, 2002, in a student who attended the school was used to define a case. Parents of cases were interviewed by telephone about disease characteristics. Disease severity was classified on the basis of the number of skin lesions and the occurrence of complications. Vaccine effectiveness was calculated by comparing varicella attack rates for any disease, for moderate to severe disease, and for severe disease among vaccinated and unvaccinated students., Results: We obtained complete information for 296 (81%) of 364 students. Varicella vaccine coverage was 74% overall and decreased by grade, from 90% in kindergarten to 60% in third grade. Attack rates increased significantly from 14% in kindergarten to 37% in third grade. Of the 53 varicella cases, 36 (68%) were unvaccinated, 12 (22%) were vaccinated, and 5 (10%) had previous disease history. Vaccine effectiveness was 89% (95% confidence interval [CI]: 79-94%) against disease of any severity, 96% (95% CI: 88-99%) against moderate to severe disease, and 100% (95% CI: undefined) against severe disease. Twenty-two percent of unvaccinated students had severe disease and 1 was hospitalized for a skin infection, whereas none of the vaccinated cases reported severe disease., Conclusion: This outbreak was attributable primarily to failure to vaccinate, especially among children in grades 1 through 3. Catch-up vaccination of susceptible older children and adolescents is especially important to prevent accumulation of susceptibility in these groups, in which the natural disease is more severe. School entry requirements will contribute to a more rapid implementation of the existing recommendations for vaccination.
- Published
- 2005
- Full Text
- View/download PDF
37. Closure of Varicella-Zoster Virus–Containing Vaccines Pregnancy Registry — United States, 2013
- Author
-
Marin, Mona, Willis, English D., Marko, Ann, Rasmussen, Sonja A., Bialek, Stephanie R., and Dana, Adrian
- Published
- 2014
38. Incidence and Clinical Characteristics of Herpes Zoster Among Children in the Varicella Vaccine Era, 2005-2009
- Author
-
Weinmann, Sheila, Chun, Colleen, Schmid, D. Scott, Roberts, Michelle, Vandermeer, Meredith, Riedlinger, Karen, Bialek, Stephanie R., and Marin, Mona
- Published
- 2013
- Full Text
- View/download PDF
39. Herpes Zoster—Related Deaths in the United States: Validity of Death Certificates and Mortality Rates, 1979–2007
- Author
-
Mahamud, Abdirahman, Marin, Mona, Nickell, Steven P., Shoemaker, Trevor, Zhang, John X., and Bialek, Stephanie R.
- Published
- 2012
- Full Text
- View/download PDF
40. Immunization of Health-Care Personnel : Recommendations of the Advisory Committee on Immunization Practices (ACIP)
- Author
-
Shefer, Abigail, Atkinson, William, Friedman, Carole, Kuhar, David T., Mootrey, Gina, Bialek, Stephanie R., Cohn, Amanda, Fiore, Anthony, Grohskopf, Lisa, Liang, Jennifer L., Lorick, Suchita A., Marin, Mona, Mintz, Eric, Murphy, Trudy V., Newton, Anna, Fiebelkorn, Amy Parker, Seward, Jane, and Wallace, Gregory
- Published
- 2011
41. Expanded Laboratory Testing for Varicella -- Minnesota, 2016-2023.
- Author
-
Ruprecht, Alison, Marin, Mona, Strain, Anna K., Harry, Katie, and Kenyon, Cynthia
- Subjects
- *
CHICKENPOX , *CLINICAL pathology , *MEDICAL laboratories , *HEALTH care industry - Abstract
The article focuses on the implementation of expanded laboratory testing for varicella in Minnesota, highlighting the increased need for laboratory confirmation due to challenges in clinically diagnosing varicella, especially in vaccinated individuals. Topics include the methods used to promote testing, the outcomes of the expanded program showing a significant increase in laboratory-confirmed varicella cases, and the importance of laboratory confirmation in guiding clinical management.
- Published
- 2024
- Full Text
- View/download PDF
42. Varicella Vaccine Exposure during Pregnancy: Data from 10 Years of the Pregnancy Registry
- Author
-
Wilson, Eileen, Goss, Mary Ann, Marin, Mona, Shields, Kristine E., Seward, Jane F., Rasmussen, Sonja A., and Sharrar, Robert G.
- Published
- 2008
- Full Text
- View/download PDF
43. Prevention of Varicella Recommendations of the Advisory Committee on Immunization Practices (ACIP)
- Author
-
Marin, Mona, Güris, Dalya, Chaves, Sandra S., Schmid, Scott, and Seward, Jane F.
- Published
- 2007
44. Epidemiology of varicella during the 2-dose varicella vaccination program--United States, 2005-2014
- Author
-
Lopez, Adriana S., Zhang, John, and Marin, Mona
- Subjects
Medical research ,Medicine, Experimental ,Vaccination ,Chickenpox ,Epidemiology ,Health - Abstract
Before availability of varicella vaccine in the United States, an estimated 4 million varicella cases, 11,000-13,500 varicella-related hospitalizations, and 100-150 varicella-related deaths occurred annually. The varicella vaccination program was implemented [...]
- Published
- 2016
45. Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review.
- Author
-
Marin, Mona, Leung, Jessica, and Gershon, Anne A.
- Subjects
- *
HERPES zoster prevention , *EXANTHEMA , *CHICKENPOX , *CINAHL database , *IMMUNE response , *IMMUNOCOMPETENT cells , *MEDICAL databases , *INFORMATION storage & retrieval systems , *MEDICAL information storage & retrieval systems , *MEDLINE , *RISK management in business , *SYSTEMATIC reviews , *CHICKENPOX vaccines , *SEVERITY of illness index , *HERPES zoster vaccines , *IMMUNOCOMPROMISED patients , *INFECTIOUS disease transmission , *DISEASE risk factors - Abstract
CONTEXT: Live vaccines usually provide robust immunity but can transmit the vaccine virus. OBJECTIVE: To assess the characteristics of secondary transmission of the vaccine-strain varicella-zoster virus (Oka strain; vOka) on the basis of the published experience with use of live varicella and zoster vaccines. DATA SOURCES: Systematic review of Medline, Embase, the Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, and Scopus databases for articles published through 2018. STUDY SELECTION: Articles that reported original data on vOka transmission from persons who received vaccines containing the live attenuated varicella-zoster virus. DATA EXTRACTION: We abstracted data to describe vOka transmission by index patient's immune status, type (varicella or herpes zoster) and severity of illness, and whether transmission was laboratory confirmed. RESULTS: Twenty articles were included. We identified 13 patients with vOka varicella after transmission from 11 immunocompetent varicella vaccine recipients. In all instances, the vaccine recipient had a rash: 6 varicella-like and 5 herpes zoster. Transmission occurred mostly to household contacts. One additional case was not considered direct transmission from a vaccine recipient, but the mechanism was uncertain. Transmission from vaccinated immunocompromised children also occurred only if the vaccine recipient developed a rash postvaccination. Secondary cases of varicella caused by vOka were mild. LIMITATIONS: It is likely that other vOka transmission cases remain unpublished. CONCLUSIONS: Healthy, vaccinated persons have minimal risk for transmitting vOka to contacts and only if a rash is present. Our findings support the existing recommendations for routine varicella vaccination and the guidance that persons with vaccine-related rash avoid contact with susceptible persons at high risk for severe varicella complications. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
46. Serological Susceptibility to Varicella Among U.S. Immigration and Customs Enforcement Detainees.
- Author
-
Varan, Aiden K., Lederman, Edith R., Stous, Shanon S., Elson, Diana, Freiman, Jennifer L., Marin, Mona, Lopez, Adriana S., Stauffer, William M., Joseph, Rachael H., and Waterman, Stephen H.
- Subjects
CHICKENPOX ,CHI-squared test ,CONFIDENCE intervals ,DISEASE susceptibility ,EMIGRATION & immigration ,PROBABILITY theory ,RESEARCH funding ,SURVEYS ,LOGISTIC regression analysis ,CHICKENPOX vaccines ,DATA analysis software ,UNDOCUMENTED immigrants ,ODDS ratio ,MANN Whitney U Test ,DISEASE risk factors ,PSYCHOLOGY - Abstract
U.S. Immigration and Customs Enforcement (ICE) is responsible for detaining unauthorized aliens during immigration proceedings. During 2014 to 2015, adult ICE detainees at a California facility were invited to complete a survey concerning self-reported varicella history and risk factors. Participants underwent serological testing for varicella-zoster virus (VZV) IgG; susceptible individuals were offered varicella vaccination. Among 400 detainees with available serology results, 48 (12%) were susceptible to varicella. Self-reported varicella history was negatively associated with susceptibility (adjusted odds ratio = 0.16; 95% confidence interval [0.07, 0.35]). Among 196 detainees reporting a positive history, 95% had VZV IgG levels suggestive of varicella immunity. Among 44 susceptible detainees offered vaccination, 86% accepted. Given relatively high varicella susceptibility, targeted screening and vaccination among ICE detainees lacking a positive history might reduce varicella transmission risks. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
47. Varicella death of an unvaccinated, previously healthy adolescent--Ohio, 2009
- Author
-
Budd, Jeremy, Fowler, Brian, Brown, Alise, Swann, Sandy, Leung, Jessica, and Marin, Mona
- Subjects
Chickenpox ,Vaccines ,Health ,American Academy of Pediatrics - Abstract
Varicella usually is a self-limited disease but sometimes can result in severe complications and death. Although infants, adults, and immunocompromised persons are at increased risk for severe disease, before varicella [...]
- Published
- 2013
48. Prevention of Varicella.
- Author
-
Marin, Mona, Güris, Dalya, Chaves, Sandra S., Schmid, Scott, and Seward, Jane F.
- Subjects
- *
CHICKENPOX , *VARICELLA-zoster virus diseases , *VACCINATION of children , *INFECTIOUS disease transmission , *GUIDELINES , *VACCINATION , *PREVENTION - Abstract
Two live, attenuated varicella zoster virus-containing vaccines are available in the United States for prevention of varicella: 1) a single-antigen varicella vaccine (VARIVAX,® Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 1995 for use among healthy children aged ≥ 12 months, adolescents, and adults; and 2) a combination measles, mumps, rubella, and varicella vaccine (ProQuad,® Merck & Co., Inc., Whitehouse Station, New Jersey), which was licensed in the United States in 2005 for use among healthy children aged 12 months-12 years. Initial Advisory Committee on Immunization Practices (ACIP) recommendations for prevention of varicella issued in 1995 (CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1996;45[No. RR-11]) included routine vaccination of children aged 12-18 months, catch-up vaccination of susceptible children aged 19 months-12 years, and vaccination of susceptible persons who have close contact with persons at high risk for serious complications (e.g., health-care personnel and family contacts of immunocompromised persons). One dose of vaccine was recommended for children aged 12 months-12 years and 2 doses, 4-8 weeks apart, for persons aged ≥ 13 years. In 1999, ACIP updated the recommendations (CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1999;48[No. RR-6]) to include establishing child care and school entry requirements, use of the vaccine following exposure and for outbreak control, use of the vaccine for certain children infected with human immunodeficiency virus, and vaccination of adolescents and adults at high risk for exposure or transmission. In June 2005 and June 2006, ACIP adopted new recommendations regarding the use of live, attenuated varicella vaccines for prevention of varicella. This report revises, updates, and replaces the 1996 and 1999 ACIP statements for prevention of varicella. The new recommendations include 1) implementation of a routine 2-dose varicella vaccination program for children, with the first dose administered at age 12-15 months and the second dose at age 4-6 years; 2) a second dose catch-up varicella vaccination for children, adolescents, and adults who previously had received 1 dose; 3) routine vaccination of all healthy persons aged ≥ 13 years without evidence of immunity; 4) prenatal assessment and postpartum vaccination; 5) expanding the use of the varicella vaccine for HIV-infected children with age-specific CD4+T lymphocyte percentages of 15%-24% and adolescents and adults with CD4+T lymphocyte counts ≥ 200 cells/µL; and 6) establishing middle school, high school, and college entry vaccination requirements. ACIP also approved criteria for evidence of immunity to varicella. [ABSTRACT FROM AUTHOR]
- Published
- 2007
49. 2767. Variation in Incidence of Pediatric Herpes Zoster by First- and Second-Dose Varicella Vaccine Formulations.
- Author
-
Weinmann, Sheila, Irving, Stephanie, Koppolu, Padma, Naleway, Allison, Belongia, Edward, Hambidge, Simon, Jackson, Michael L, Klein, Nicola, Lewin, Bruno, Liles, Elizabeth, Marin, Mona, Smith, Ning, Weintraub, Eric, and Chun, Colleen
- Subjects
CHICKENPOX ,HERPES zoster ,VARICELLA-zoster virus diseases ,MMR vaccines ,CHICKENPOX vaccines ,VACCINES - Abstract
Background Varicella (VAR) and measles-mumps-rubella (MMR) vaccines are recommended for children at ages 12–15 months and 4–6 years. These are administered as separate MMR and VAR vaccines (MMR+VAR) or as combined measles-mumps-rubella-varicella (MMRV) vaccine. Herpes zoster (HZ), caused by wild-type or vaccine-strain varicella-zoster virus, can occur in children after varicella vaccination. It is unknown whether HZ incidence after varicella vaccination varies by vaccine formulation or simultaneous receipt of MMR. Methods Using data from six integrated health systems, we examined HZ incidence among children who turned 12 months old during 2003–2008 and received varicella and MMR vaccines according to routine recommendations. All HZ cases ≥ 21 days after first varicella vaccination were identified using ICD-9 codes from inpatient, outpatient, emergency room encounters, and claims data, through 2014. HZ incidence was examined by vaccine formulation (MMR+VAR, MMRV, or VAR without same-day MMR) and doses received and compared using incidence rate ratios (IRR). Results Among 199,797 children, we identified 601 HZ cases. Crude HZ incidence after first-dose MMR+VAR (18.6 [95% CI 11.1–29.2] cases/100,000 person-years) was similar to the rate after first-dose MMRV (17.9 [95% CI 10.6–28.3] cases/100,000 person-years), but approximately double the rate among those with first-dose VAR without same-day MMR (7.5 [95% CI 3.1–15.0] cases/100,000 person-years); see Table 1. The IRR for HZ after first-dose MMR+VAR or MMRV, compared with VAR, was 2.5 (95% CI 1.4–4.4; P = 0.002). When examining any first or second dose formulation, crude HZ incidence was lower after the second varicella vaccine dose (13.9 cases/100,000 person-years), than in the period before the second dose (i.e. between first and second doses or after the first dose in children with only one dose; 21.8 cases/100,000 person-years, P < 0.0001). HZ incidence was also lower after two varicella vaccine doses in each of the three first-dose formulation groups. Conclusion HZ incidence among children varied by first-dose varicella vaccine formulation and number of varicella vaccine doses. Regardless of the first-dose varicella vaccine formulation, children who received two vaccine doses had lower HZ incidence after the second dose. Disclosures All authors: No reported disclosures. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. Updated Recommendations for Use of VariZIG -- United States, 2013.
- Author
-
Marin, Mona, Bialek, Stephanie R., and Seward, Jane F.
- Subjects
- *
CHICKENPOX vaccines , *CHICKENPOX , *VARICELLA-zoster virus diseases , *VACCINATION - Abstract
The article discusses the U.S. Centers for Disease Control and Prevention's (CDC) updated recommendations for the use of VariZIG, a varicella zoster immune globulin preparation from Cangene Corp. The CDC recommendations replace those issued in 2007 by the Advisory Committee on Immunization Practices (ACIP). The harmonization of the CDC recommendations for VariZIG use with those of the American Academy of Pediatrics (AAP) is also cited.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.